Otsuka Positive Topline Results From Two Pivotal Phase 3 ADHD Trials

 

• Centanafadine, an investigational compound for the treatment of ADHD, demonstrated statistically significant improvements vs. placebo for the primary efficacy endpoint in both clinical trials
• ADHD is one of the most common neurodevelopmental disorders of childhood, with an estimated six million children and adolescents diagnosed in the U.S.¹
• Otsuka will discuss these results with health authorities

https://www.biospace.com/article/releases/otsuka-pharmaceutical-announces-positive-topline-results-from-two-pivotal-phase-3-trials-of-centanafadine-as-a-treatment-for-adolescents-and-children-with-attention-deficit-hyperactivity-disorder-adhd-/